Effectiveness of switching from intravenous to subcutaneous infliximab in inflammatory bowel disease patients: A combined analysis of real-world evidence
Effectiveness of switching from intravenous to subcutaneous infliximab in inflammatory bowel disease patients: A combined analysis of real-world evidence
Effectiveness of switching from intravenous to subcutaneous infliximab in inflammatory bowel disease patients: A combined analysis of real-world evidence
Cummings F et al.
ECCO 2024; P712
Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first-line for maintenance treatment of adultpatients with moderate-to-severe Crohn’s disease
Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first-line for maintenance treatment of adultpatients with moderate-to-severe Crohn’s disease
Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first-line for maintenance treatment of adultpatients with moderate-to-severe Crohn’s disease
Schreiber S et al.
ECCO 2024; P623
Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study
Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study
Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study
Bouguen et al.
ECCO 2024; P884
Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to anendoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study
Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to anendoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study
Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to anendoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study
Sands BE et al.
ECCO 2024; P983
Subcutanous infliximab (CT-P13 SC) as maintenance therapie for Crohn’s disease : 2 years results of the LIBERTY-CD study
Subcutanous infliximab (CT-P13 SC) as maintenance therapie for Crohn’s disease : 2 years results of the LIBERTY-CD study
Subcutanous infliximab (CT-P13 SC) as maintenance therapie for Crohn’s disease : 2 years results of the LIBERTY-CD study
Colombel JF et al.
ECCO 2024; P902
Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study
Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study
Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study
Sands BE et al.
ECCO 2024; P957
Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CT-P43 or Reference Ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis: 1-Year Result
Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CT-P43 or Reference Ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis: 1-Year Result
Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CT-P43 or Reference Ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis: 1-Year Result
Papp K et al. 2023
EADV 2023 P0792
Poster
Subcutaneous Infliximab (CT-P13 SC) dose escalation as an option for managing the loss of response in Inflammatory Bowel Disease from LIBERTY-UC study and LIBERTY-CD study
Subcutaneous Infliximab (CT-P13 SC) dose escalation as an option for managing the loss of response in Inflammatory Bowel Disease from LIBERTY-UC study and LIBERTY-CD study
Subcutaneous Infliximab (CT-P13 SC) dose escalation as an option for managing the loss of response in Inflammatory Bowel Disease from LIBERTY-UC study and LIBERTY-CD study
Danese et al. 2023
UEG Week 2023 MP362
Efficacy, safety and immunogenicity of Subcutaneous Infliximab (CT-P13 SC) monotherapy versus combination therapy with Immunosuppressants from LIBERTY-CD study and LIBERTY-UC study
Efficacy, safety and immunogenicity of Subcutaneous Infliximab (CT-P13 SC) monotherapy versus combination therapy with Immunosuppressants from LIBERTY-CD study and LIBERTY-UC study
Efficacy, safety and immunogenicity of Subcutaneous Infliximab (CT-P13 SC) monotherapy versus combination therapy with Immunosuppressants from LIBERTY-CD study and LIBERTY-UC study
Schreiber et al. 2023
UEG Week 2023 PP0757
Treatment Discontinuation Due to Lack of Efficacy During Maintenance Phase of Infliximab or Vedolizumab Treatment in Patients with Crohn’s Disease: A Comparative Analysis of Randomized Controlled Trials
Treatment Discontinuation Due to Lack of Efficacy During Maintenance Phase of Infliximab or Vedolizumab Treatment in Patients with Crohn’s Disease: A Comparative Analysis of Randomized Controlled Trials
Treatment Discontinuation Due to Lack of Efficacy During Maintenance Phase of Infliximab or Vedolizumab Treatment in Patients with Crohn’s Disease: A Comparative Analysis of Randomized Controlled Trials
Ferrante et al. 2023
UEG Week 2023
Network meta-analysis to evaluate the comparative efficacy of biologics for maintenance treatment of adult patients with Crohn’s disease
Network meta-analysis to evaluate the comparative efficacy of biologics for maintenance treatment of adult patients with Crohn’s disease